Skip to main content
. 2018 Apr 3;34(2):339–346. doi: 10.1093/ndt/gfy061

FIGURE 1.

FIGURE 1

Serum FGF23 concentrations at screening, post-phosphate-binder washout and at the end of study treatment with tenapanor or placebo. Geometric means (CV, percentage) at post-washout reported previously [27]. b.i.d., twice daily; EOT/ET, end of treatment/early termination; q.d., once daily.